Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 10/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setileuton SCHEMBL1528740 | 1.00 | ALOX5 (1.00) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| Setileuton SCHEMBL13691961 | 1.00 | ALOX5 (1.00) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| Setileuton SCHEMBL1528741 | 1.00 | ALOX5 (1.00) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| Setileuton SCHEMBL1528921 | 0.91 | ALOX5 (0.83) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| Setileuton SCHEMBL1528924 | 0.91 | ALOX5 (0.83) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| SCHEMBL4080470 | 0.90 | ALOX5 (0.82) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| SCHEMBL20780187 | 0.90 | ALOX5 (0.82) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| SCHEMBL4076133 | 0.90 | ALOX5 (0.81) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| SCHEMBL4087806 | 0.90 | ALOX5 (0.81) | ALOX5GRM2KCNH2KDM4EALDH1A1 | |
| SCHEMBL4078770 | 0.90 | ALOX5 (0.81) | ALOX5GRM2KCNH2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299347-A1 | METHODS AND COMPOSITIONS TO TREAT HUNTINGTON'S DISEASE BY TARGETING ALOX5- MEDIATED FERROPTOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-09-12 | — | — | US | claimed |
| US-20250276002-A1 | Particles with RNA Cleaving Nucleobase Polymers and Uses for Managing Inflammatory Disorders | UNIV EMORY (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4608876-A2 | ENDOCYTIC AGENTS | BioVentures, LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| EP-4548972-A2 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-3744714-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| US-20240336582-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | US | disclosed |
| US-20240299347-A1 | METHODS AND COMPOSITIONS TO TREAT HUNTINGTON'S DISEASE BY TARGETING ALOX5- MEDIATED FERROPTOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-09-12 | — | — | US | disclosed |
| EP-3463388-B1 | PARTICLES WITH RNA CLEAVING NUCLEOBASE POLYMERS AND USES FOR MANAGING INFLAMMATORY DISORDERS | UNIV EMORY (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-107096014-B | Monovalent metal cation dry powder for inhalation | 普马特里克斯营业公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-4008326-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | Pulmatrix Operating Company, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220169616-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | MERCK SHARP & DOHME CORP. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220133737-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | BIOPHARMA CREDIT PLC (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20220062391-A1 | ENHANCING EPITHELIAL OR ENDOTHELIAL BARRIER FUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133737-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | DPEP1, TPP1, DPP9 | ALOX5 3493/4885GRM2 3355/4885KCNH2 1305/4885 |
| US-20240299347-A1 | METHODS AND COMPOSITIONS TO TREAT HUNTINGTON'S DISEASE BY TARGETING ALOX5- MEDIATED FERROPTOSIS | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885GRM2 298/4885KCNH2 4831/4885 |
| US-20240336582-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | ALOX5 2844/4885GRM2 2368/4885KCNH2 2478/4885 |
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | DPEP1, TPP1, DPP9 | ALOX5 3330/4885GRM2 3337/4885KCNH2 1139/4885 |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | AVPR2, AVPR1A, VHL | ALOX5 4428/4885GRM2 2948/4885KCNH2 392/4885 |
| US-20220169616-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | AVPR2, AVPR1A, VHL | ALOX5 4428/4885GRM2 2948/4885KCNH2 392/4885 |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | PDE8B, RPS27A, PDE8A | ALOX5 1974/4885GRM2 4853/4885KCNH2 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.